WALTHAM, Mass., April 11, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a patent covering the utility of its iontophoretic…
WALTHAM, Mass., Sept. 11, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company focused on developing and commercializing products using two proprietary platform technologies for treating diseases and disorders of the eye, today announced its launch of a social media presence on Facebook, Twitter and LinkedIn. Because the…
Transaction enhances development pipeline with addition of new ophthalmic platform technology First Jade product to enter clinic later this year WALTHAM, Mass., March 07, 2016 — Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye,…
WALTHAM, MA, December 2, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has received additional positive topline data in its corneal wound repair pivotal study. As previously announced, the results of this pivotal study…
WALTHAM, Mass., May 24, 2016 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (the “Company”) announced today that it has entered into an At The Market Issuance (“ATM”) Sales Agreement, dated May 24, 2016, with H.C. Wainwright & Co., LLC (the “Sales Agent”), under which the Company may, at its discretion and from time to time during the…
WALTHAM, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) today announced top-line data from its study evaluating the potential of EyeGate’s Ocular Bandage Gel (OBG) to help clinicians better manage patients with punctate epitheliopathies (PE) due to pathologies such as dry eye. Randall J Olson, M.D., CEO and Chair of the…
Data confirms results from earlier study WALTHAM, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) today announced top-line data from its study evaluating the potential of EyeGate’s Ocular Bandage Gel (OBG) to help clinicians better manage corneal epithelial defects in patients following photorefractive keratectomy (PRK) surgery, compared to current standard of…
Top line Data expected in Q3 2018 WALTHAM, Mass., April 06, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), today announced completion of patient enrollment for the pivotal Phase 3 clinical study of its EGP-437 combination product for the treatment of non-infectious anterior uveitis. Non-infectious anterior uveitis is characterized by the inflammation of…
Triggers Milestone Payment under Global Licensing Agreement with Valeant Pharmaceuticals WALTHAM, Mass., Nov. 08, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two platform technologies for treating diseases and disorders of the eye, has completed enrollment in the double-masked, randomized, placebo-controlled Phase 2b trial of its EGP-437…
WALTHAM, MA / ACCESSWIRE / March 26, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) has met with the U.S. Food and Drug Administration (“FDA”) regarding its Ocular Bandage Gel (“OBG”) product and has confirmed its path to a de novo filing. The FDA has agreed that based on the strength of…